1. Abelson, R. (2020). Major U.S. health insurers report big profits, benefiting from the pandemic. New York Times. Retrieved August 5, 2020, from https://www.nytimes.com/2020/08/05/health/covid-insurance-profits.html.
2. Barker, J. (2019). U.S. Supreme Court denies Maryland bid to revive law aimed at preventing “monstrous” generic drug price increases. The Baltimore Sun. Retrieved February 19, 2019, from https://www.baltimoresun.com/politics/bs-md-drug-price-gouging-decision-20190219-story.html.
3. Berk, J. B., & DeMarzo, P. M. (2017). Corporate finance (4th ed.). Boston: Pearson.
4. Berndt, E. R., Nass, D., Kleinrock, M., & Aitken, M. (2015). Decline in economic returns from new drugs raises questions about sustaining innovations. Health Affairs, 34(2), 245–252.
5. Bernstein, L. (2018). Largest U.S. drug distributor accused of illegally handling cancer medication. The Washington Post. Retrieved April 6, 2018, from https://www.washingtonpost.com/national/health-science/largest-us-drug-distributor-accused-of-illegally-handling-cancer-medication/2018/04/06/11ff42a8-39c2-11e8-acd5-35eac230e514_story.html?utm_term=.916f8e97c1a8.